|
Aztreonam Injection
DEFINITION
Aztreonam Injection is a sterile solution of Aztreonam and Arginine and a suitable osmolality adjusting substance in Water for Injection. It contains NLT 90.0% and NMT 120.0% of the labeled amount of aztreonam (C13H17N5O8S2).
IDENTIFICATION
• A.
The retention times of the major peaks of the Sample solution correspond to those of the Standard solution, as obtained in the Assay.
ASSAY
• Procedure
Buffer:
1.15 g/L of monobasic ammonium phosphate in water. Before final dilution, adjust with phosphoric acid to a pH of 2.0 ± 0.1.
Mobile phase:
Acetonitrile and Buffer (75:25).
System suitability solution:
0.2 mg/mL of each of USP Aztreonam RS and USP Open Ring Aztreonam RS in Mobile phase
Standard solution:
0.2 mg/mL each of USP Aztreonam RS and USP l-Arginine RS in Mobile phase
Sample solution:
Equivalent to 0.2 mg/mL of aztreonam from Injection in Mobile phase
Chromatographic system
Mode:
LC
Detector:
UV 206 nm
Pre-column:
4.6-mm × 5- to 10-cm saturator precolumn containing packing L27
Column:
4-mm × 25-cm analytical column containing packing L20
Flow rate:
1 mL/min
Injection size:
20 µL
System suitability
Sample:
System suitability solution
[NoteThe relative retention times for aztreonam and open ring aztreonam are 0.8 and 1.0, respectively. The relative retention times for aztreonam and arginine are 0.3 and 1.0, respectively. ]
Suitability requirements
Resolution:
NLT 2.0 between aztreonam and open ring aztreonam
Column efficiency:
NLT 1000 theoretical plates determined from the aztreonam peak
Tailing factor:
NMT 2.0 for the aztreonam peak
Relative standard deviation:
NMT 2.0% for the aztreonam peak
Analysis
Samples:
Standard solution and Sample solution
Calculate the percentage of aztreonam (C13H17N5O8S2) in the portion of Injection taken:
Result = (rU/rS) × (CS/CU) × P × F × 100
Acceptance criteria:
90.0%120.0%
SPECIFIC TESTS
• Pyrogen Test
• Sterility Tests
• pH
• Particulate Matter in Injections
ADDITIONAL REQUIREMENTS
• Packaging and Storage:
Preserve as described under Injections
• Labeling:
It meets the requirements for Injections
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 2291
|